Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals

Set Alert for Deals

Alvotech Starts European Trial For High-Concentration Adalimumab

Icelandic developer Alvotech is looking to set itself apart from the pack offering biosimilar rivals to Humira by conducting a Phase III clinical trial for an alternative to AbbVie’s high-concentration 100mg/ml version of adalimumab, the world’s best-selling drug.
Biosimilars Immune Disorders

Alvogen Fails In Revlimid IPR Attempt

Alvogen’s inter partes review petition challenging a Revlimid patent in the US has been denied by the PTAB, following similar denials of petitions by Dr Reddy’s over three other Revlimid patents.

Intellectual Property United States

Saphris Asenapine Ruling Is Bounced Back By US Appeals Court

District court errors on failing to address potential motivation to develop sublingual formulations, as well as on claim construction for label carve-outs, have led the US Court of Appeals to vacate and remand a patent validity and infringement ruling on Allergan’s Saphris asenapine antipsychotic.
United States Intellectual Property

UK’s CMA Will Not Take Action Over Remicade Discount Scheme

The UK’s competition regulator will not take action against MSD over a suspected anti-competitive discount scheme for Remicade (infliximab), despite an earlier provisional finding that MSD had a dominant market position and the scheme was in breach of competition law.

Legal Issues Biosimilars

Canadian Body Welcomes Pharmacare Report

An interim report on implementing national pharmacare in Canada that highlights the importance of cost savings and access to medicines has been welcomed by local off-patent industry body the CGPA.

Market Intelligence Canada

Coherus Claims Pegfilgrastim Payer Parity, But Parries Sales Queries

Coherus BioSciences is hailing US payers’ responses to its January launch of its Udenyca pegfilgrastim biosimilar; but the US-based developer sidestepped investors’ questions around sales figures.
Biosimilars Pricing Strategies
See All
UsernamePublicRestriction

Register